[1]李律宇,罗淼,李宁,等.基于网络药理学方法、分子对接技术及动物实验探讨参威骨痹汤治疗骨质疏松症的作用机制[J].中医正骨,2024,36(05):1-12,44.
　LI Lyuyu,LUO Miao,LI Ning,et al.Analysis of mechanism of Shenwei Gubi Tang(参威骨痹汤)against osteoporosis based on the network pharmacology approach,molecular docking techniques and animal experimentation[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2024,36(05):1-12,44.
点击复制

基于网络药理学方法、分子对接技术及动物实验探讨参威骨痹汤治疗骨质疏松症的作用机制()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第36卷
期数:
2024年05期
页码:
1-12,44
栏目:
基础研究
出版日期:
2024-05-20

文章信息/Info

Title:
Analysis of mechanism of Shenwei Gubi Tang(参威骨痹汤)against osteoporosis based on the network pharmacology approach,molecular docking techniques and animal experimentation
作者:
李律宇1; 罗淼2; 李宁3; 李德光1; 廖江龙1; 邓力1; 刘敏2; 王晓颖1; 冮顺奎1
1.昆明市中医医院,云南 昆明 650500; 2.云南中医药大学第三附属医院,云南 昆明 650500; 3.云南中医药大学第一临床医学院,云南 昆明 650500
Author(s):
LI Lyuyu1; LUO Miao2;  LI Ning3; LI Deguang1; LIAO Jianglong1; DENG Li1; LIU Min2; WANG Xiaoying1;  GANG Shunkui1
1.Kunming Municipal Hospital of Traditional Chinese Medicine,Kunming 650500,Yunnan,China 2.The Third Affiliated Hospital of Yunnan University of Chinese Medicine,Kunming 650500,Yunnan,China 3.The First Clinical Medical College of Yunnan University of Chinese Medicine,Kunming 650500,Yunnan,China
关键词:
骨质疏松;  参威骨痹汤;  网络药理学;  分子对接模拟;  动物实验
Keywords:
osteoporosis;  Shenwei Gubi Tang;  network pharmacology;  molecular docking simulation;  animal experimentation
摘要:
目的:探讨参威骨痹汤治疗骨质疏松症(osteoporosis,OP)的作用机制。方法:①网络药理学研究。采用超高效液相色谱-质谱法鉴定参威骨痹汤中的化合物,采用网络药理学方法初步筛选参威骨痹汤治疗OP的关键活性成分和靶点。②分子对接验证。采用分子对接技术验证网络药理学研究确定的参威骨痹汤治疗OP的关键活性成分与靶点的结合效果,从中筛选结合效果最好的组合。③动物实验验证。将60只雌性C57BL/6JNifdc小鼠随机等分为5组,模型组和参威骨痹汤低、中、高剂量组小鼠通过双侧卵巢切除手术进行OP造模,假手术组小鼠仅切取卵巢周围等体积的脂肪组织。参威骨痹汤低、中、高剂量组小鼠分别按照14.95 g·kg-1·d-1、29.9 g·kg-1·d-1、59.8 g·kg-1·d-1以参威骨痹汤药液灌胃,假手术组和模型组小鼠以等体积生理盐水灌胃。药物干预8周后,取股骨进行Micro-CT检查和组织病理学观察(HE染色和抗酒石酸酸性磷酸酶染色),采用实时定量PCR技术测定胫骨组织中根据网络药理学和分子对接技术确定的关键靶点基因的mRNA表达水平。结果:①网络药理学研究结果。网络药理学研究结果显示,SRC、促分裂原活化的蛋白激酶3(mitogen-activated protein kinase 3,MAPK3)、MAPK1、磷脂酰肌醇3-激酶调节亚基1(phosphatidylinositol-3-kinase regulatory subunit 1,PI3KR1)、信号转导及转录活化因子3为参威骨痹汤治疗OP的关键靶点,五味子丙素、10-姜酚、对羟基苯甲酸丁酯、倍半萜内酯和香豆雌酚为参威骨痹汤治疗OP的关键活性成分。②分子对接验证结果。分子对接结果显示,参威骨痹汤治疗OP关键活性成分与关键靶点的结合能均小于-5 kJ·mol-1,表明结合效果良好,其中靶点SRC、MAPK3、PI3KR1与活性成分五味子丙素、10-姜酚、对羟基苯甲酸丁酯的结合效果更好。③动物实验验证结果。Micro-CT检查及组织病理学观察结果显示,参威骨痹汤能改善OP模型小鼠的骨质疏松程度,其中中剂量参威骨痹汤效果更好。实时定量PCR测定结果显示,参威骨痹汤中剂量组胫骨组织中SRC mRNA和MAPK3 mRNA表达水平低于模型组,PI3KR1 mRNA表达水平与模型组比较差异无统计学意义。结论:参威骨痹汤治疗OP的机制可能是通过五味子丙素、10-姜酚、对羟基苯甲酸丁酯等成分调控SRC、PI3KR1、MAPK3的表达来调节骨代谢。
Abstract:
Objective:To explore the mechanism of Shenwei Gubi Tang(参威骨痹汤,SWGBT)against osteoporosis(OP).Methods:①Network pharmacology research.The ingredients in SWGBT were identified by using ultra-high performance liquid chromatography-quadrupole-orbitrap mass spectrometry(UHPLC-QE-MS),and the key active ingredients and action targets of SWGBT against OP were preliminarily screened using the network pharmacology approach.②Validation by molecular docking.The binding effects between the key active ingredients and the targets of SWGBT against OP determined by network pharmacology were validated by molecular docking techniques,and the combination with the best binding effect was screened.③Verification by animal experimentation.Sixty female C57BL/6JNifdc mice were selected and randomized into model group,low-dose SWGBT(L-SWGBT)group,medium-dose SWGBT(M-SWGBT)group,high-dose SWGBT(H-SWGBT)group and sham-operated group.The mice in model group,L-SWGBT group,M-SWGBT group and H-SWGBT group were subjected to bilateral ovariectomy for inducing OP; while the ones in sham-operated group were merely removed an equal volume of peri-ovarian adipose tissues.After successful modeling,the mice in L-SWGBT group,M-SWGBT group and H-SWGBT group were intervened by intragastric administration with 14.95,29.9,59.8 g/(kg·d)SWGBT,respectively; while the ones in sham-operated group and model group with the same dose of normal saline.After 8-week drug intervention,the rats were sacrificed and their femurs were harvested for Micro-CT examination and observation on histopathological changes through HE staining and tartrate-resistant acid phosphatase(TRAP)staining.Furthermore,the mRNA expression levels of key target genes(determined by network pharmacology approach and molecular docking techniques)in tibia tissues were detected by using real-time quantitative PCR(RT-qPCR).Results:①The results of network pharmacology research showed that SRC,mitogen-activated protein kinase 3(MAPK3),MAPK1,phosphatidylinositol-3-kinase regulatory subunit 1(PI3KR1),and signal transducer and activator of transcription 3(STAT3)were the key targets of SWGBT against OP,and the schisandrin C,10-gingerol,butyl p-hydroxybenzoate,sesquiterpene lactone,and coumestrol were the key active ingredients of SWGBT against OP.②The results of molecular docking showed that the key active ingredients of SWGBT against OP had good binding ability to the key targets with the binding energy less than -5.0 kJ/mol,and the targets including SRC,MAPK3,and PI3KR1 exhibited better binding effects with the active ingredients including schisandrin C,10-gingerol,and butyl p-hydroxybenzoate.③The results of Micro-CT examination and histopathological observation showed that the SWGBT could improve the degree of OP in OP model mice,with the medium-dose SWGBT displaying better effects.The results of RT-qPCR showed that the mRNA levels of SRC and MAPK3 were lowly expressed in the tibia tissues of OP model mice in M-SWGBT group compared to model group,while,the mRNA expression level of PI3KR1 was not significantly different from that of model group.Conclusion:The SWGBT may regulate bone metabolism for treatment of OP through adjusting the expression of SRC,PI3KR1 and MAPK3 via the ingredients such as schisandrin C,10-gingerol and butyl p-hydroxybenzoate.

参考文献/References:

[1] NOH J Y,YANG Y,JUNG H.Molecular mechanisms and emerging therapeutics for osteoporosis[J].Int J Mol Sci,2020,21(20):7623.
[2] NGUYEN D T,HO-LE T P,PHAM L,et al.BONEcheck:a digital tool for personalized bone health assessment[J].Osteoporos Sarcopenia,2023,9(3):79-87.
[3] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[4] 李律宇,杨春艳,侯敏,等.参威骨痹汤治疗肝肾亏虚、寒湿痹阻型骨关节炎103例临床观察[J].云南中医学院学报,2015,38(4):67-69.
[5] KIM Y,BRODT M D,TANG S Y,et al.MicroCT for scanning and analysis of mouse bones[J].Methods Mol Biol,2021,2230:169-198.
[6] 彭广,葛殊玮,王凡,等.孙达武教授治疗老年性骨质疏松症临证经验[J].光明中医,2024,39(2):251-254.
[7] 郭超,张兴彩,王卫国,等.基于网络药理学探讨“山药-杜仲”药对治疗骨质疏松症的作用机制[J].西部中医药,2024,37(2):48-53.
[8] 王柳蕴,李芸佳,胡熠婷,等.基于脏腑理论探讨骨质疏松症的治疗[J].光明中医,2023,38(17):3479-3482.
[9] 张希,东方梓涵,李江,等.小红参免疫作用及质量标志物预测分析[J].亚太传统医药,2022,18(7):193-197.
[10] 张光云,童英,杨丽萍,等.小红参临床应用与药理学研究概况[J].中国民族民间医药,2020,29(12):51-54.
[11] 李慧,包永睿,王帅,等.中药茜草抗氧化、抗炎、抗肿瘤不同药用部位精准研究[J].世界科学技术-中医药现代化,2019,21(3):401-407.
[12] 赵继荣,杨文通,陈文,等.威灵仙有效化学成分及镇痛机制研究进展[J].中华中医药学刊,2022,40(9):9-12.
[13] 郎小琴,高越,周叶,等.牛膝多糖对老年骨质疏松大鼠模型骨代谢及生物力学特征的影响[J].中华全科医学,2019,17(4):547-550.
[14] 王艳,周广举,严宗逊,等.川牛膝在去卵巢大鼠体内的骨保护作用[J].中国骨质疏松杂志,2015,21(8):918-921.
[15] 董佳梓,鞠大宏,贾朝娟,等.桑寄生、枸杞子、桑椹对去卵巢大鼠骨质疏松症的治疗作用及其机理探讨[J].中国中医基础医学杂志,2010,16(6):483-486.
[16] 熊伟,赵亮.盐炙杜仲对维甲酸诱导骨质疏松大鼠生化指标及骨密度的影响[J].时珍国医国药,2020,31(8):1866-1867.
[17] 曹刘丹,胡晨,顾琼,等.独活化学成分及抗骨质疏松活性评价[J].时珍国医国药,2022,33(12):2918-2923.
[18] LI Y,ZHANG J,ZHANG L,et al.Systems pharmacology to decipher the combinational anti-migraine effects of Tianshu formula[J].J Ethnopharmacol,2015,174:45-56.
[19] 马艳春,吴文轩,胡建辉,等.当归的化学成分及药理作用研究进展[J].中医药学报,2022,50(1):111-114.
[20] THOMAS S M,BRUGGE J S.Cellular functions regulated by Src family kinases[J].Annu Rev Cell Dev Biol,1997,13:513-609.
[21] BOYCE B F,YONEDA T,LOWE C,et al.Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice[J].J Clin Invest,1992,90(4):1622-1627.
[22] ZHENG L Z,WANG X L,CAO H J,et al.Src siRNA prevents corticosteroid-associated osteoporosis in a rabbit model[J].Bone,2016,83:190-196.
[23] SALVADORI L,BELLADONNA M L,CASTIGLIONI B,et al.Kymasin up natural product inhibits osteoclastogenesis and improves osteoblast activity by modulating Src and p38 MAPK[J].Nutrients,2022,14(15):3503.
[24] MARZIA M,SIMS N A,VOIT S,et al.Decreased c-Src expression enhances osteoblast differentiation and bone formation[J].J Cell Biol,2000,151(2):311-320.
[25] TANIGUCHI C M,EMANUELLI B,KAHN C R.Critical nodes in signalling pathways:insights into insulin action[J].Nat Rev Mol Cell Biol,2006,7(2):85-96.
[26] MI B,XIONG Y,CHEN L,et al.CircRNA AFF4 promotes osteoblast cells proliferation and inhibits apoptosis via the Mir-7223-5p/PIK3R1 axis[J].Aging(Albany NY),2019,11(24):11988-12001.
[27] CUI J,LI X,WANG S,et al.Triptolide prevents bone loss via suppressing osteoclastogenesis through inhibiting PI3K-AKT-NFATc1 pathway[J].J Cell Mol Med,2020,24(11):6149-6161.
[28] HAN J,LI L,ZHANG C,et al.Eucommia,cuscuta,and dryna-ria extracts ameliorate glucocorticoid-induced osteoporosis by inhibiting osteoclastogenesis through PI3K/Akt pathway[J].Front Pharmacol,2021,12:772944.
[29] LI M,YANG N,HAO L,et al.Melatonin inhibits the ferroptosis pathway in rat bone marrow mesenchymal stem cells by activating the PI3K/AKT/mTOR signaling axis to attenuate steroid-induced osteoporosis[J].Oxid Med Cell Longev,2022:8223737.
[30] ZHANG Y T,HU C,ZHANG S X,et al.Euphoesulatin a prevents osteoclast differentiation and bone loss via inhibiting RANKL-induced ROS production and NF-κB and MAPK signal pathways[J].Bioorg Chem,2022,119:105511.
[31] XU M,SONG D,XIE X,et al.CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca2+ oscillations and NF-κB/MAPK signaling pathways[J].iScience,2023,26(10):107760.
[32] XIAO L,ZHONG M,HUANG Y,et al.Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways[J].Aging(Albany NY),2020,12(21):21706-21729.
[33] LI X,JIANG J,YANG Z,et al.Galangin suppresses RANKL-induced osteoclastogenesis via inhibiting MAPK and NF-κB signalling pathways[J].J Cell Mol Med,2021,25(11):4988-5000.
[34] HOU G Q,GUO C,SONG G H,et al.Lipopolysaccharide(LPS)promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells[J].Int J Mol Med,2013,32(2):503-510.
[35] ZHANG J,ZHENG X,ZHAO F,et al.UHMWPE wear particles and dendritic cells promote osteoclastogenesis of RAW264.7 cells through RANK-activated NF-κB/MAPK/AKT pathways[J].Int J Clin Exp Pathol,2017,10(9):9400-9408.
[36] ROSKOSKI R Jr.ERK1/2 MAP kinases:structure,function,and regulation[J].Pharmacol Res,2012,66(2):105-143.
[37] KYRIAKIS J M,AVRUCH J.Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation[J].Physiol Rev,2001,81(2):807-869.
[38] HU X H,YANG X Y,LIAN J,et al.Moringa oleifera leaf attenuate osteoporosis in ovariectomized rats by modulating gut microbiota composition and MAPK signaling pathway[J].Biomed Pharmacother,2023,161:114434.

相似文献/References:

[1]李林军.应用膨胀式椎弓根螺钉内固定治疗合并骨质疏松的 胸腰椎退行性疾病[J].中医正骨,2015,27(08):49.
[2]韩艳,温利平,刘娜,等.补肾活血方对去卵巢大鼠骨代谢及骨密度的影响[J].中医正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(补肾活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(05):7.
[3]李学朋,朱立国.骨疏康胶囊对去卵巢大鼠骨小梁的影响[J].中医正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康胶囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(05):12.
[4]陈冠军,陈扬,庄汝杰.可灌注骨水泥椎弓根螺钉系统 在老年腰椎疾患手术中的应用[J].中医正骨,2015,27(02):40.
[5]王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(05):27.
[6]黄建华,黄建武,李慧辉,等.加味左归丸对绝经后骨质疏松症肝肾不足证 患者骨密度的影响[J].中医正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(05):19.
[7]项旻,杨虹,林爱菊,等.绝经后2型糖尿病患者骨质疏松与血微量元素的关系研究[J].中医正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(05):20.
[8]史晓林,李春雯,张志强.弱阳离子磁珠分离技术和基质辅助激光解吸电离飞行时间质谱技术在原发性Ⅰ型骨质疏松症血清标志蛋白筛选中的应用[J].中医正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(05):5.
[9]李明,徐明雄,冯左基,等.自拟壮骨方治疗绝经后骨质疏松症的疗效及作用机制研究[J].中医正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(05):21.
[10]陈俊杰,李晴晴,夏瑢.脂代谢及血清内脂素水平与绝经后骨质疏松症的 相关性研究[J].中医正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(05):16.

备注/Memo

备注/Memo:
基金项目:云南省科学技术厅-中医联合专项面上项目(202101AG070053,202301AZ070001-091)
通讯作者:冮顺奎 E-mail:2031291588@qq.com
更新日期/Last Update: 1900-01-01